Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare...( Excellarate Phase 2b Clinical...),Health

Excellarate Phase 2b Clinical Trial Data

Earlier this week, Cardium announced that all patients enrolled in the Company's MATRIX clinical study have completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data around the end of September 2009. The Phase 2b MATRIX clinical trial is a prospective, randomized, double-blind, placebo-controlled study of Excellarate for the potential treatment of chronic diabetic foot ulcers. This landmark gene therapy clinical study was designed to evaluate safety and efficacy in patients receiving the Excellarate drug candidate compared to placebo controls. A standard of care reference arm was also included in the study. The safety and key efficacy measures of the MATRIX study include complete wound closure, time to complete wound closure, absolute and percent change in ulcer area, and wound healing trajectories at various time points, as well as other safety and healing metrics, which will be used to develop the planned Phase 3 clinical study. In addition, following the initial 12-week efficacy evaluation period, patients whose wounds have successfully closed will be followed for three months to further evaluate wound healing durability.

To learn more about the Excellarate product candidate and the MATRIX clinical study, click here to view a television segment featuring an investigator of the study, Dr. Vickie Driver, D.P.M., Director of Research, Foot Care, Department of Surgery at Boston Medical University and Medical Center, and